Taken together, these findings identify Jak2 and Lyn as additional drug targets in CML and further highlight the important role of tyrosine-phosphorylated Gab2 as a driver of CML [86,91,95]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.